Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

BACKGROUND: This analysis was carried out to evaluate the long-term survival of patients with metastatic melanoma who received ipilimumab, a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte antigen-4, in clinical trials. PATIENTS AND METHODS: Patients received ipilimumab in one o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Wolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K., Cykowski, L., de Pril, V., Humphrey, R., Lebbé, C.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2013
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081656/
https://ncbi.nlm.nih.gov/pubmed/23666915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt161
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares